Artivion (AORT) revenue breakdown
By segment, North America is the largest at 50% of fiscal 2025 revenue; LATAM grew fastest, 24% a year over 4 years.
By product, Aortic stent grafts is the largest at 36% of fiscal 2025 revenue, growing 14% a year over 7 years.
Revenue by segment
Fiscal years, as Artivion reports them in its 10-K filings; fiscal 2025 total $441M.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | — | — | — | — | — | $158M | $168M | $188M | $198M | $222M | 50% |
| EMEA | — | — | — | — | — | $109M | $104M | $115M | $132M | $151M | 34% |
| APAC | — | — | — | — | — | $22M | $28M | $34M | $37M | $44M | 10% |
| LATAM | — | — | — | — | — | $10M | $14M | $18M | $22M | $24M | 5% |
| Medical devices | $114M | $120M | $187M | $197M | $179M | — | — | — | — | — | — |
| Preservation services | $66M | $70M | $75M | $79M | $74M | — | — | — | — | — | — |
Revenue by product
Fiscal years, as Artivion reports them in its 10-K filings; fiscal 2025 total $441M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aortic stent grafts | — | — | $63M | $65M | $62M | $85M | $93M | $107M | $123M | $159M | 36% |
| On-X | — | — | $45M | $50M | $48M | $57M | $64M | $75M | $84M | $102M | 23% |
| Preservation services | — | — | — | $79M | $74M | $77M | $83M | $93M | $98M | $96M | 22% |
| Surgical sealants | — | — | $67M | $69M | $62M | $71M | $65M | $68M | $74M | $77M | 17% |
| Other | — | — | — | $14M | $8M | $8M | $8M | $11M | $9M | $8M | 2% |
| Domestic Hospitals | $124M | $128M | — | — | — | — | — | — | — | — | — |
| Vascular Tissues | — | — | $40M | — | — | — | — | — | — | — | — |
| Cardiac Tissues | — | — | $36M | — | — | — | — | — | — | — | — |
| International Distributors | $32M | $31M | — | — | — | — | — | — | — | — | — |
| International Hospitals | $17M | $24M | — | — | — | — | — | — | — | — | — |
| CardioGenesis Cardiac Laser Therapy | $8M | $7M | $6M | — | — | — | — | — | — | — | — |
| PerClot | — | — | $4M | — | — | — | — | — | — | — | — |
| PhotoFix | — | — | $3M | — | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Artivion reports them in its 10-K filings; fiscal 2025 total $441M.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Foreign | $49M | $55M | $118M | $126M | $115M | $148M | $153M | $175M | $199M | $227M | 51% |
| UNITED STATES | $132M | $135M | $145M | $151M | $138M | $151M | $161M | $179M | $190M | $214M | 49% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AORT.
Open AORT in InvestinglyQuestions
Where does Artivion make its money?
In fiscal 2025, by segment: North America $222M, EMEA $151M, APAC $44M, LATAM $24M.
From Artivion's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.